Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System

NCT03339310 | Completed FDA Device

• 2 other identifiers: CP OPT2017-005FIX-HF-5C2
• Study Type: interventional
• Target: 60
• Locations: 2 countries
• Sites: 10

Brief Summary

This is a multicenter, prospective, single-arm study of the Optimizer Smart System with 2-leads

Conditions

Heart Failure; Congestive Heart Failure; Chronic Heart Disease; CHF

Keywords

CCM Therapy; 2-Lead; FIX-HF-5C2; Optimizer

Outcome Measures

Primary Outcomes (2)

• Change in exercise tolerance quantified by peak VO2 measured on cardiopulmonary exercise stress testing (CPX).

  Device efficacy will be assessed as change in exercise tolerance quantified by peak VO2 measured on cardiopulmonary exercise stress testing (CPX). Subjects on device under FIX-HF-5C2 protocol will be compared to subjects on control under FIX-HF-5C protocol with respect to peak V02 mean change at 24-weeks from baseline.

  24 weeks

• Optimizer-device and -procedure related complication rate

  Subjects experiencing an Optimizer device- or procedure-related complication through the 24-week study period, as determined by an independent events committee.

  24 weeks

Secondary Outcomes (1)

• Total CCM delivery comparing 2 and 3-lead device configurations

  24 weeks

Study Arms (1)

Optimizer Smart System with 2-leads

EXPERIMENTAL

All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).

Device: Optimizer Smart System with 2-leads

Interventions

Optimizer Smart System with 2-leads DEVICE

The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.

Also known as: Optimizer Smart System

Optimizer Smart System with 2-leads

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects who are 18 years of age or older
• Subject is male or a non-pregnant female
• Subjects who have a baseline ejection fraction greater than or equal to 25% and less than or equal to 45% by echocardiography determined by the echocardiography core laboratory.
• Subjects who have been treated for heart failure for at least 90 days (including treatment with a β-blocker for at least 90 days unless the subject is intolerant) and are in New York Heart Association functional Class III and IV at the time of enrollment.
• Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure according to guideline recommendations. For patients with EF≤35%, this regimen shall consist of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and β-blocker. Angiotensin receptor -neprilysin inhibitor (ARNI) may be substituted for ACE inhibitors or ARBs and Ivabradine may also be considered in subjects with a heart rate \>70bpm. Stable is defined as no more than a 100% increase or 50% decrease in dose.
• Subjects who, in the opinion of the Principal Investigator (based on the current guidelines for clinical practice), have a clinical indication for an implanted cardiac defibrillator (ICD, e.g., EF≤35%) and/or pacemaker, must have an existing device unless the patient refuses to undergo the implantation of such device for personal reasons.
• Subjects who are willing and able to return for all follow-up visits.

You may not qualify if:

• Subjects whose baseline peak VO2 is \<9 or \>20 ml O2/min/kg. The qualifying CPX test must be deemed adequate.
• Subjects who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease.
• Subjects who have clinically significant angina pectoris, consisting of angina during daily life (i.e., Canadian Cardiovascular Society Angina score of II or more), an episode of unstable angina within 30 days before enrollment, or angina and/or ECG changes during exercise testing performed during baseline evaluation.
• Subjects hospitalized for heart failure requiring acute treatment with intravenous loop diuretics, IV inotropes or hemofiltration within 30 days before enrollment and baseline testing or subjects receiving any form of positive inotropic support within 30 days before enrollment, including continuous IV inotrope therapy.
• Subjects having a PR interval greater than 375ms.
• Subjects whose exercise tolerance is limited by a condition other than heart failure (e.g., angina, COPD, peripheral vascular disease, orthopedic or rheumatologic conditions) or who are unable to perform baseline stress testing.
• Subjects who are scheduled for a CABG or a PTCA procedure, or who have undergone a CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.
• Subjects who have a biventricular pacing system, an accepted indication for such a device, or a QRS width of 130ms or greater.
• Subjects who have had a myocardial infarction within 90 days of enrollment.
• Subjects who have mechanical tricuspid valve.
• Subjects who have a prior heart transplant.
• Subjects on dialysis.
• Subjects who are participating in another experimental protocol.
• Subjects who are unable to provide informed consent.

Sponsors & Collaborators

• Impulse Dynamics: lead

Study Sites (10)

Chan Heart Rhythm Institute

Mesa, Arizona, 85206, United States

Location

Southwest Cardiology Associates

Mesa, Arizona, 85206, United States

Location

Cardiovascular Consultants

Phoenix, Arizona, 85032, United States

Location

Arizona Arrhythmia Consultants

Scottsdale, Arizona, 85251, United States

Location

Pima Heart Physicians, PC

Tucson, Arizona, 85712, United States

Location

Baptist Health Systems

Lexington, Illinois, 40503, United States

Location

Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States

Location

Dallas VA Hospital

Dallas, Texas, 75216, United States

Location

CHRISTUS Trinity Mother Frances

Tyler, Texas, 75701, United States

Location

University Hospital gGmbH Bergmannsheil

Bochum, 44789, Germany

Location

Related Publications (1)

• Wiegn P, Chan R, Jost C, Saville BR, Parise H, Prutchi D, Carson PE, Stagg A, Goldsmith RL, Burkhoff D. Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study. Circ Heart Fail. 2020 Apr;13(4):e006512. doi: 10.1161/CIRCHEARTFAILURE.119.006512. Epub 2020 Apr 8.

  PMID: 32264716 DERIVED

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Study Officials

• David D. Gutterman, MD

  Medical College of Wisconsin

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Optimizer Smart System

Study Record Dates

• First Submitted: October 23, 2017
• First Posted: November 13, 2017
• Study Start: October 23, 2017
• Primary Completion: October 30, 2019
• Study Completion: October 30, 2019
• Last Updated: January 14, 2020

Record last verified: 2020-01

Locations

DE (1); US (9)